Sterling Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Sterling Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,369	Closed	-$21.3K	–	3253
2025 Q4	$21.3K	Hold	1,369	–	–	﹤0.01%	2195
2025 Q3	$20K	Hold	1,369	–	–	﹤0.01%	2139
2025 Q2	$21.2K	Hold	1,369	–	–	﹤0.01%	1778
2025 Q1	$20.4K	Sell	1,369 -11,754	-90%	-$165K	﹤0.01%	1644
2024 Q4	$174K	Sell	13,123 -20,607	-61%	-$283K	﹤0.01%	1309
2024 Q3	$480K	Buy	+33,730	New	+$478K	0.01%	877
2019 Q3	$381K	Sell	22,165 -67	-0.3%	-$1.16K	﹤0.01%	781
2019 Q2	$394K	Buy	22,232 +2,911	+15%	+$53K	﹤0.01%	781
2019 Q1	$394K	Buy	19,321 +5,500	+40%	+$111K	﹤0.01%	765
2018 Q4	$232K	Buy	+13,821	New	+$233K	﹤0.01%	809

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sterling Capital Management's TAK Position: Q1 2026 in Review

Sterling Capital Management sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 1,369 shares — an estimated $21.3K sold.

Sterling Capital Management first reported a position in TAK in Q4 2018 and held it in 10 quarters. The position peaked at $480K in Q3 2024. 361 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Sterling Capital Management reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Sterling Capital Management sold 1,369 Takeda Pharmaceutical shares in Q1 2026, an estimated $21.3K.
Sterling Capital Management first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 10 quarters.
Sterling Capital Management's Takeda Pharmaceutical position peaked at $480K in Q3 2024.
361 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.